INTRODUCTION
The hallmark of type 1 diabetes (T1D) is its origin due to autoimmune processes that destroy the insulin-producing b cells. It would, therefore, be expected that the genes predisposing an individual to risk of developing T1D would be different from those which confer risk of type 2 diabetes, which does not have an autoimmune basis. It should also be expected that there would be some overlap in the genetic risk factors between T1D and other autoimmune diseases. Over the last few years, improved technology has enabled discovery of genes for many diseases, not least T1D. These discoveries have confirmed the above predictions. However, much still remains to be discovered. This review will summarize gene discoveries made over the past year, as well as discussing how these genes may contribute to disease. Given the well known and well characterized association of human leukocyte antigen (HLA) genes with T1D risk, recent reviews of which may be found in references [1,2 & ], more emphasis will be given here to the non-HLA genes.
The recent findings on T1D genetics indicate several emerging themes: known genetic associations have been followed up and replicated in additional populations, new T1D risk genes have been identified, characterization of candidate genes indicate molecular pathways of disease and commonalities with other autoimmune disease, existing resources, notably from the type 1 Diabetes Genetics Consortium (T1DGC) [3,4,5 && ] and the Wellcome Trust Case-Control Consortium (WTCCC) [6] , have been leveraged to generate new methods and discoveries; and despite the large number of susceptibility genes identified, there seems to be distinct clinical subtypes of T1D. In this review, recent studies in the field of T1D genetics will be discussed in relation to these themes.
Confirmation of previously reported type 1 diabetes risk genes
It is important that genetic findings can be replicated in independent cohorts of cases. For the purposes of this discussion, the largest single Genome-wide Association Study (GWAS) conducted on T1D [4] will be taken as the canonical study. Readers may refer to this study and recent reviews [1,2 & ] for references to earlier studies of individual associations of genetic polymorphisms with T1D. Table 1 lists the genes that were found to be associated with T1D in that study, and which have been replicated in the last year in additional cohorts or with new methods. ] examined the association signal on chromosome 12q23, near the ERBB3 gene. By resequencing an 80-kb region, they found over 100 new single nucleotide polymorphisms (SNPs). Genotyping a total of 42 SNPs spanning over 200 kb, they found 15 had significant T1D association, with two providing separate evidence for association. One was located in an exon of ERBB3, whereas the other novel SNP was in an intergenic region. Espino-Paisan et al. [12 & ] also found evidence for association with two separate SNPs in the 12q23 region in their analysis of Spanish T1D cases. Thus, this region appears to make an unusually complicated contribution to T1D susceptibility.
Another complicated locus is IL2RA, encoding the receptor for the cytokine interleukin-2. Again, multiple SNPs appear to make independent contributions to susceptibility [ [15] in Russian and Spanish T1D cases, respectively. In contrast to the high throughput genotyping used in many studies, Di Stasio et al.
[23] found that blue eyes were a significant predictor of T1D in an Italian sample, confirming a previous study from northern Europe.
New type 1 diabetes risk genes: when is enough enough?
Despite over 50 loci previously found to have significant association with T1D, more risk factors are still being identified. Table 1 also lists new genes reported as being associated with T1D since January 2011. Many of these genes were found using either new analytical methods or by examining particular candidate genes.
By virtue of the increased power of their GWAS meta-analysis cohort, Bradfield et al. [7 && ] found two new loci and possibly a third. The novel loci were defined by a SNP in the LMO7 gene on chromosome 13q22 and another in a intergenic region of chromosome 6q27 with a 900 kb associated interval which is relatively gene rich. The third SNP tagged a region of linkage disequilibrium extending over 800 kb from 25.5 Mb on chromosome 2p; this region may overlap with a locus previously implicated by SNP rs2165738 at 24.5 Mb [4].
The major histocompatibility complex exerts the highest genetic contribution to T1D susceptibility [1,2 & ] and is likely to harbour additional risk genes in addition to the well known HLA class II genes. Baschal et al. [17 & ] followed up a signal at the telomeric end of the major histocompatibility complex they had studied previously. They accounted for effects of HLA by logistic regression, mapping a high-risk haplotype to a 20 kb region containing an uncharacterised gene. Using novel algorithms for phasing the multiallelic HLA genotypes and for partitioning HLA strata in conditional testing to analyse WTCCC and T1DGC data, Cheung et al. 
KEY POINTS
The genetics of T1D is very complex, with over 60 genes now identified as contributing to its risk.
Many of these genes also contribute to related diseases.
Systems genetics and conventional approaches are required to understand the molecular basis by which these genes contribute to disease.
The resources and data assembled for these studies support further modelling and refinement.
A challenge for researchers is to find ways in which the genetic data will be helpful to clinicians in understanding and managing the disease. ] found evidence for association with a polymorphism in codon 72 of TRP53 in an Italian cohort; this is close to the rs16956936 SNP tagging the DNAH2 region [4] and must be replicated in larger cohorts.
Genetic overlap of type 1 diabetes with other diseases of immune dysregulation
It is to be expected that genes which lead to dysregulation of immune responses could be associated with many diseases which have either an autoimmune basis or some other breakdown of appropriate regulation. Accordingly, other diseases with a similar response should show association with T1D risk genes, and vice versa. Together with epidemiological and clinical evidence, this rationale is ] applied the same rationale to define factors causing occurrence of multiple autoimmune diseases. Drawing on the T1DGC dataset, they found that related autoimmune diseases were more likely to be found in women having a family history of related diseases, later onset of T1D, and increased antibodies to glutamic acid decarboxylase (GAD).
A clear example of using genetics to resolve clinical conditions was provided by Gan et al.
who tested a variant in the gene encoding the lymphocyte surface marker Cd226 in cases of Addison's Disease or autoimmune polyendocrinopathy type 2. Their findings suggested that there was no association with isolated Addison's Disease and that any association with these diseases was by virtue of the underlying association with T1D, providing a means to define patient subtypes in these conditions.
Functional characterization of type 1 diabetes risk alleles
Gene identification is the important first step on the road to understanding the molecular basis of ]; 2 refers to the associated LD region is $800 kb and has several genes (this region is also near the associated SNP rs2165738 [4]); 3 refers to P values shown are conditional on appropriate HLA DR/DQ genotypes; 4 refers to reference [8 && ] found evidence for association at this locus, but the statistical model was not consistent with the first report; 5 refers to overlaps with and provides a stronger signal for the SH2B3 region. Chr, chromosome; SNP, single-nucleotide polymorphism. Ã For clarity, P values are expressed as negative logarithms (i.e. Àlog P).
disease. Perhaps the best detailed investigation of T1D risk alleles recently was by Davison et al. [28 && ], who studied the T1D-associated SNP in an intron of CLEC16A. They found that a nearby gene, DEX1, was a more likely candidate for T1D susceptibility than CLEC16A, because the relevant DNA variant affected expression of DEX1. They showed a physical interaction of the CLEC16A intron with the promoter of DEX1 but not with the CLEC16A promoter [28
&&
]. This study highlights the important point that the best candidate gene is not necessarily the one closest to the most associated SNP.
CTLA4 was one of the earliest non-HLA T1D risk genes identified. Gerold et al. ] undertook a similar approach at the proteomic level to identify Huntingtin-interacting protein 14 as a strong candidate. It was found to be required for glucose-stimulated insulin release and promoted b-cell survival via antiapoptotic effects. Vandiedonck et al. [34 && ] conducted a detailed investigation of gene expression across the major histocompatibility complex, finding that many haplotype-specific differences in gene expression and frequent alternative splicing.
Using type 1 diabetes Genome-wide Association Study data to develop new genetic methods
The wealth of data generated by the T1DGC and WTCCC has enabled development of new analytical methods and strategies. It is beyond the scope of this review to discuss these individually, but note that they make advances in three main areas: enhanced discovery of the causative SNPs in T1D genes [ ] found new association signals by increasing the density of the marker map and using haplotypes. They used information from the 1000 Genomes Project to impute genotypes in the WTCCC cohort. Their approach was validated by 'discovering' loci (near IL2RA and SH2B3) that had been overlooked by the original WTCCC study but were found subsequently. They further refined the SH2B3-associated signal to a SNP near the CUX2 gene.
Heterogeneity
On the one hand, the disease known as T1D is easy to diagnose and, despite heterogeneity including a wide age of onset, it is generally regarded as a single disease. On the other hand, with over 60 loci now known to contribute to its risk, and doubtless with more to be uncovered, it could be considered as incredibly heterogeneous in a genetic sense: essentially, each person affected by T1D (except identical twins) would have a unique combination of genotypes at all these risk alleles. The implication is that each person may have a different molecular genetic pathway to disease. The truth probably lies between these extremes, so we could consider what recent evidence there is for discrete T1D disease subtypes.
Heterogeneity of T1D is perhaps most apparent in age at onset, autoantibody production, and associated autoimmune diseases. In turn, these traits can also show differences according to HLA genotypes. Earlier genetic linkage studies did show differences in linkage to non-HLA genes according to factors such as HLA status, autoantibody status, disease onset, and gender (e.g., [43] which mapped the IDDM13 locus that is now confirmed via association with SLC11A1 [16 & ]). It is reasonable to suggest that the first level of heterogeneity may be determined by genotype at HLA class II genes, which then drives association with other HLA-linked genes, non-HLA genes, and ultimately the clinical traits mentioned.
The availability of over 4000 affected sib-pair families recruited and characterized by the T1DGC allowed a comprehensive study of the effect of stratification on genetic linkage [5 && ]. Consistent with earlier studies (e.g., [43] ), certain loci did show increased evidence of linkage following stratification, although no locus apart from HLA showed strong linkage as expected based on the large numbers of families available. Although this may be due to inclusion of families from countries having wide ethnic and environmental differences, the study nevertheless supported the notion that T1D is a heterogeneous disease caused by interaction of different HLA haplotypes with an apparently random combination of alleles from the constellation of non-HLA risk genes [5 && ].
Insights into type 1 diabetes Morahan
Nevertheless, certain association of alleles at HLA and other loci may be found: as mentioned above, new loci within or near the HLA complex have been implicated by stratifying on HLA status [17 & ,18 & ]. In addition, it would be expected that some risk genes would be more likely to bring about an earlier onset, and this was reported for PTPN2, TRP53, and IFIH1 [15,21 & ,44 & ]. Slower progression to disease would suggest slower loss of residual b cell function, and this was demonstrated in a study of the PTPN22 risk variant [45] . Adult onset of T1D represents the extreme of the age at diagnosis trait, but an extensive study of a German cohort found few differences compared with pediatric-onset cases; it was concluded that a lower overall genetic load was thought to slow the progression of clinical T1D [46 && ]. A primary role of HLA is in presentation of antigen to T cells, so it would be expected that a key correlate of heterogeneity would be that different antigens would be recognized by the immune system according to HLA genotype. Brorsson et al. ] reported similar results: more antibodies in older onset cases, whereas specificity of autoantibodies showed differences in association with different HLA genes: GAD and insulinoma-associated antigen-2 antibodies had the strongest association with HLA-DRB1, whereas GAD antibody levels were associated with DQB1 alleles. Tying autoantibody status with underlying physiology, Cubas-Dueñas et al. [49 && ] found that GAD antibodies were more frequently found in patients who showed insulin resistance. In contrast, the presence of antibodies recognizing insulin antigen 2 (IA2) was not accompanied by insulin resistance, but tended to be produced by patients with detectable circulating enterovirus RNA [49 && ]. These results suggest heterogeneity in T1D cases brought about by interplay between different environmental and genetic factors.
CONCLUSION
The array of over 60 genes now associated with T1D susceptibility presents a bewildering challenge for the nongeneticist. How can all these genes be taken into account when considering a child's risk status? Do all or any of these genes have any bearing on disease management? As noted above, it is difficult to determine how any one gene may impact on a disease pathway if there really is independent association of a subset of SNPs from a collection of 60 or more, interacting with at least three different high-risk HLA genotypes. Worse, there seems to be no compelling reason for clinicians to learn an exhausting list of genes and SNPs if these have no impact on clinical management. The challenge for geneticists seems not to derive longer lists with more and more genes of smaller and smaller impact, but to construct a framework that both simplifies and integrates what we currently know into an easily understood and clinically relevant model. This gene, more commonly known as SH2B3, was confirmed in Russian patients, and the susceptibility allele was shown to be associated with increased lymphocyte proliferation.
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